Biomarker discovery and clinical proteomics

Jerzy Silberring, Pawel S Ciborowski

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis). Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity, specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue. Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.

Original languageEnglish (US)
Pages (from-to)128-140
Number of pages13
JournalTrAC - Trends in Analytical Chemistry
Volume29
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

proteomics
Biomarkers
biomarker
body fluid
Body fluids
sample preparation
Mass spectrometry
Screening
drug
gel
mass spectrometry
Gels
Throughput
protein
Pharmaceutical Preparations
Proteomics
Proteins
method

Keywords

  • Bioinformatics
  • Biomarker
  • Clinical
  • Electrophoresis
  • Immunodepletion
  • Liquid chromatography
  • Mass spectrometry
  • Protein array
  • Proteomics
  • Sample preparation

ASJC Scopus subject areas

  • Analytical Chemistry
  • Spectroscopy

Cite this

Biomarker discovery and clinical proteomics. / Silberring, Jerzy; Ciborowski, Pawel S.

In: TrAC - Trends in Analytical Chemistry, Vol. 29, No. 2, 01.02.2010, p. 128-140.

Research output: Contribution to journalReview article

@article{03e4ce9ce4704da3bed66c2fd8c2eacc,
title = "Biomarker discovery and clinical proteomics",
abstract = "New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis). Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity, specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue. Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.",
keywords = "Bioinformatics, Biomarker, Clinical, Electrophoresis, Immunodepletion, Liquid chromatography, Mass spectrometry, Protein array, Proteomics, Sample preparation",
author = "Jerzy Silberring and Ciborowski, {Pawel S}",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.trac.2009.11.007",
language = "English (US)",
volume = "29",
pages = "128--140",
journal = "TrAC - Trends in Analytical Chemistry",
issn = "0165-9936",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Biomarker discovery and clinical proteomics

AU - Silberring, Jerzy

AU - Ciborowski, Pawel S

PY - 2010/2/1

Y1 - 2010/2/1

N2 - New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis). Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity, specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue. Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.

AB - New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis). Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity, specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue. Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.

KW - Bioinformatics

KW - Biomarker

KW - Clinical

KW - Electrophoresis

KW - Immunodepletion

KW - Liquid chromatography

KW - Mass spectrometry

KW - Protein array

KW - Proteomics

KW - Sample preparation

UR - http://www.scopus.com/inward/record.url?scp=77949289299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949289299&partnerID=8YFLogxK

U2 - 10.1016/j.trac.2009.11.007

DO - 10.1016/j.trac.2009.11.007

M3 - Review article

C2 - 20174458

AN - SCOPUS:77949289299

VL - 29

SP - 128

EP - 140

JO - TrAC - Trends in Analytical Chemistry

JF - TrAC - Trends in Analytical Chemistry

SN - 0165-9936

IS - 2

ER -